Filgotinib effective for rheumatoid arthritis in real-world study

A real-world Italian study found the JAK inhibitor Filgotinib was effective and well-tolerated for rheumatoid arthritis. Nearly half of the 254 participants had hard-to-treat RA, showing sustained benefits and adherence. This adds to the picture of how these targeted inflammation blockers work outside of clinical trials.